MapLight Therapeutics, Inc. (MPLT) shareholders
Close on Nov 17, 2026Market cap $304.70MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Catalyst4, Inc. Joint filing with Robert Brown (49.90%), Ekemini Riley (49.90%) and 1 more | 27,536,011 | 49.90% | 13D (active) amendment | Aug 14, 2026 |
| Mark Vorsatz Joint filing with Catalyst4, Inc. (45.10%), Robert Brown (45.10%) and 1 more | 19,697,464 | 45.10% | 13D (active) | Oct 28, 2025 |
| Forbion Growth III Management B.V. Joint filing with Forbion Growth Opportunities Fund III Cooperatief U.A. (7.10%) | 3,226,400 | 7.10% | 13G (passive) | Dec 31, 2025 |
| T. Rowe Price Investment Management, Inc. | 3,137,558 | 7.40% | 13G (passive) amendment | Mar 31, 2026 |
| Nan Fung Group Holdings Limited Joint filing with NF Investment Holdings Limited (5.50%) | 2,915,874 | 5.50% | 13G (passive) | Aug 13, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MPLT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Novo Holdings A/S | 3,686,622 | 7.95% | $132.13M | – | 7.67% |
| Fcpm Iii Services B.V. | 3,226,400 | 6.96% | $115.63M | – | 15.41% |
| T. Rowe Price Investment Management, Inc. | 2,781,728 | 6.00% | $99.70M | −20,209 | 0.07% |
| Goldman Sachs Group Inc | 1,948,312 | 4.20% | $69.83M | −46,561 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,422,935 | 3.07% | $51.00M | +1,310,227 | 0.01% |
| BlackRock, Inc. | 1,025,134 | 2.21% | $36.74M | −314,597 | 0.00% |
| Nan Fung Group Holdings Ltd | 971,253 | 2.09% | $34.81M | – | 26.47% |
| 5AM Venture Management, LLC | 950,011 | 2.05% | $34.05M | – | 11.83% |
| Sanofi | 912,041 | 1.97% | $32.69M | – | 6.12% |
| State Street Corp | 852,150 | 1.84% | $30.54M | +513,034 | 0.00% |
| FMR LLC | 823,556 | 1.78% | $29.52M | +619,055 | 0.00% |
| Vanguard Capital Management LLC | 784,150 | 1.69% | $28.10M | +64,330 | 0.00% |
| Blue Owl Capital Holdings LP | 729,929 | 1.57% | $26.16M | −276,000 | 3.94% |
| Paradigm Biocapital Advisors LP | 685,852 | 1.48% | $24.58M | New | 0.46% |
| Pivotal bioVenture Partners Investment Advisor LLC | 611,446 | 1.32% | $21.91M | −1 | 7.12% |
| Velan Capital Investment Management LP | 492,893 | 1.06% | $17.67M | – | 10.76% |
| Siren, L.L.C. | 450,000 | 0.97% | $16.13M | – | 0.33% |
| Capital World Investors | 415,730 | 0.90% | $14.90M | New | 0.00% |
| Geode Capital Management, LLC | 402,051 | 0.87% | $14.41M | −79,150 | 0.00% |
| Baker Bros. Advisors LP | 364,705 | 0.79% | $13.07M | – | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 106 | 26M | 56.6% | 37 / 21 | 30 / 10 | 4M | 3M |
| Q1 2026 | 81 | 25M | 53.5% | 22 / 26 | 14 / 14 | 4M | 4M |
| Q4 2025 | 74 | 26M | 55.8% | 74 / 0 | 0 / 0 | 26M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MPLT | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 625,046 | 1.35% | $22.40M | 0.24% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 605,601 | 1.31% | $21.70M | 0.21% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 552,279 | 1.19% | $19.79M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 498,428 | 1.07% | $17.86M | 0.17% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 406,402 | 0.88% | $5.29M | 0.07% | Jul 31, 2026 |
| SMALLCAP World Fund Inc | 404,389 | 0.87% | $14.49M | 0.02% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 402,792 | 0.87% | $14.44M | 0.15% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 398,809 | 0.86% | $14.29M | 0.10% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 342,343 | 0.74% | $12.27M | 0.24% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 267,770 | 0.58% | $9.60M | 0.01% | Jun 30, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 263,529 | 0.57% | $3.43M | 0.07% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 216,312 | 0.47% | $7.75M | 0.01% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 202,900 | 0.44% | $2.64M | 0.12% | Jul 31, 2026 |
| Fidelity Series Small Cap Core Fund | 138,400 | 0.30% | $1.80M | 0.11% | Jul 31, 2026 |
| Vanguard Explorer Fund | 131,368 | 0.28% | $1.71M | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher A. Kroeger | Chief Executive Officer, Director | 1,297,099 | 2.80% | Oct 16, 2026 |
| Anatol Kreitzer | Chief Discovery Officer | 168,678 | 0.36% | Oct 16, 2026 |
| Jonathan Gillis | CAO and Interim CFO | 142,315 | 0.31% | Oct 16, 2026 |
| James Woodruff Lillie | Chief Scientific Officer | 198,597 | 0.43% | Oct 16, 2026 |
| Erin Pennock Foff | Chief Medical Officer | 296,906 | 0.64% | Oct 16, 2026 |
| Kristopher Hanson | General Counsel | 128,024 | 0.28% | Oct 16, 2026 |
| Vishwas Setia | Chief Financial Officer | 356,256 | 0.77% | May 6, 2026 |
| Troy Cox | Director | 23,484 | 0.05% | Jul 28, 2026 |
| George Pavlov | Director | 28,932 | 0.06% | Jun 25, 2026 |
| Martin Babler | Director | 7,864 | 0.02% | Jun 25, 2026 |
| Maria C. Walker | Director | 62,703 | 0.14% | Jun 25, 2026 |
| Timothy John Garnett | Director | 67,581 | 0.15% | Jun 25, 2026 |
| Nanna Liebach Luneborg | Director | 3,932 | 0.01% | Jun 25, 2026 |
| Robert C. Malenka | Director | 348,138 | 0.75% | Apr 17, 2026 |
| James D. Trenkle | Director | – | – | Oct 27, 2025 |
| Catalyst4, Inc. | 10% owner | 25,306,689 | 54.57% | Aug 18, 2026 |
| Holdings A/S Novo | 10% owner | 2,733,681 | 5.89% | Oct 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Anatol Kreitzer Chief Discovery Officer | Oct 15, 2026 | Sale | −12,248 | $7.84 | $96.02K | 168,678 |
| Erin Pennock Foff Chief Medical Officer | Oct 15, 2026 | Sale | −15,355 | $8.08 | $124.07K | 296,906 |
| Kristopher Hanson General Counsel | Oct 15, 2026 | Sale | −9,020 | $8.08 | $72.88K | 128,024 |
| James Woodruff Lillie Chief Scientific Officer | Oct 15, 2026 | Sale | −11,513 | $8.08 | $93.03K | 198,597 |
| Jonathan Gillis CAO and Interim CFO | Oct 15, 2026 | Sale | −10,167 | $8.08 | $82.15K | 142,315 |
| Christopher A. Kroeger Chief Executive Officer, Director | Oct 15, 2026 | Sale | −73,691 | $8.08 | $595.42K | 1,195,909 |
| Kristopher Hanson General Counsel | Sep 16, 2026 | Sale(10b5-1 plan) | −16,509 | $11.67 | $192.66K | 137,044 |
| Kristopher Hanson General Counsel | Aug 17, 2026 | Award | +7,730 | – | – | 153,553 |
| Christopher A. Kroeger Chief Executive Officer, Director | Aug 17, 2026 | Award | +23,145 | – | – | 1,269,600 |
| Erin Pennock Foff Chief Medical Officer | Aug 17, 2026 | Award | +13,360 | – | – | 312,261 |
| James Woodruff Lillie Chief Scientific Officer | Aug 17, 2026 | Award | +7,730 | – | – | 210,110 |
| Anatol Kreitzer Chief Discovery Officer | Aug 17, 2026 | Award | +6,020 | – | – | 180,926 |
| Jonathan Gillis CAO and Interim CFO | Aug 17, 2026 | Award | +2,222 | – | – | 152,482 |
| Jonathan Gillis CAO and Interim CFO | Aug 17, 2026 | Award | +6,020 | – | – | 150,260 |
| Catalyst4, Inc. 10% owner | Aug 14, 2026 | Buy | +4,400,000 | $11.38 | $50.07M | 25,306,689 |
| James Woodruff Lillie Chief Scientific Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −22,082 | $12.54 | $276.91K | 202,380 |
| Catalyst4, Inc. 10% owner | Jul 30, 2026 | Buy | +1,000,000 | $13.00 | $13.00M | 20,906,689 |
| Catalyst4, Inc. 10% owner | Jul 29, 2026 | Buy | +3,000 | $12.63 | $37.89K | 19,906,689 |
| Catalyst4, Inc. 10% owner | Jul 28, 2026 | Buy | +141,088 | $10.74 | $1.52M | 19,838,552 |
| Catalyst4, Inc. 10% owner | Jul 28, 2026 | Buy | +65,137 | $11.69 | $761.45K | 19,903,689 |
| Troy Cox Director | Jul 28, 2026 | Buy | +15,620 | $9.52 | $148.70K | 15,620 |
| Jonathan Gillis CAO and Interim CFO | Jul 17, 2026 | Sale(10b5-1 plan) | −900 | $38.17 | $34.35K | 144,240 |
| Jonathan Gillis CAO and Interim CFO | Jul 17, 2026 | Sale(10b5-1 plan) | −600 | $36.51 | $21.91K | 162,109 |
| Jonathan Gillis CAO and Interim CFO | Jul 17, 2026 | Sale(10b5-1 plan) | −16,969 | $37.61 | $638.20K | 145,140 |
| Anatol Kreitzer Chief Discovery Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −2,833 | $37.05 | $104.96K | 189,246 |
| Anatol Kreitzer Chief Discovery Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −14,140 | $37.70 | $533.08K | 175,106 |
| Anatol Kreitzer Chief Discovery Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −200 | $38.39 | $7.68K | 174,906 |
| James Woodruff Lillie Chief Scientific Officer | Jul 17, 2026 | Sale | −2,077 | $37.90 | $78.72K | 224,462 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 17, 2026 | Sale | −16,779 | $37.90 | $635.92K | 1,246,455 |
| Kristopher Hanson General Counsel | Jul 17, 2026 | Sale | −1,130 | $37.90 | $42.83K | 145,823 |
| Erin Pennock Foff Chief Medical Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −3,656 | $37.90 | $138.56K | 298,901 |
| Jonathan Gillis CAO and Interim CFO | Jul 16, 2026 | Sale(10b5-1 plan) | −1,476 | $37.44 | $55.26K | 162,709 |
| Jonathan Gillis CAO and Interim CFO | Jul 16, 2026 | Sale(10b5-1 plan) | −6,979 | $36.66 | $255.85K | 164,185 |
| Anatol Kreitzer Chief Discovery Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −7,464 | $36.66 | $273.63K | 193,671 |
| Anatol Kreitzer Chief Discovery Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −1,592 | $37.44 | $59.60K | 192,079 |
| James Woodruff Lillie Chief Scientific Officer | Jul 16, 2026 | Sale | −5,009 | $36.45 | $182.58K | 230,077 |
| James Woodruff Lillie Chief Scientific Officer | Jul 16, 2026 | Sale | −3,526 | $37.26 | $131.38K | 226,551 |
| James Woodruff Lillie Chief Scientific Officer | Jul 16, 2026 | Sale | −12 | $37.96 | $456 | 226,539 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 16, 2026 | Sale | −40,899 | $36.46 | $1.49M | 1,291,417 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 16, 2026 | Sale | −92 | $37.96 | $3.49K | 1,263,234 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 16, 2026 | Sale | −28,091 | $37.26 | $1.05M | 1,263,326 |
| Kristopher Hanson General Counsel | Jul 16, 2026 | Sale | −11 | $37.96 | $418 | 146,953 |
| Kristopher Hanson General Counsel | Jul 16, 2026 | Sale | −4,776 | $36.45 | $174.09K | 150,295 |
| Kristopher Hanson General Counsel | Jul 16, 2026 | Sale | −3,331 | $37.26 | $124.11K | 146,964 |
| Erin Pennock Foff Chief Medical Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −9,163 | $36.46 | $334.08K | 308,441 |
| Erin Pennock Foff Chief Medical Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −5,865 | $37.26 | $218.53K | 302,576 |
| Erin Pennock Foff Chief Medical Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −19 | $37.96 | $721 | 302,557 |
| Jonathan Gillis CAO and Interim CFO | Jul 15, 2026 | Sale(10b5-1 plan) | −4,699 | $36.94 | $173.58K | 171,164 |
| Jonathan Gillis CAO and Interim CFO | Jul 15, 2026 | Sale(10b5-1 plan) | −5,356 | $36.13 | $193.51K | 175,863 |
| Anatol Kreitzer Chief Discovery Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −5,545 | $36.13 | $200.34K | 205,645 |
| Anatol Kreitzer Chief Discovery Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −4,510 | $36.94 | $166.60K | 201,135 |
| James Woodruff Lillie Chief Scientific Officer | Jul 15, 2026 | Sale | −2,238 | $36.00 | $80.57K | 240,491 |
| James Woodruff Lillie Chief Scientific Officer | Jul 15, 2026 | Sale | −12 | $37.54 | $450 | 235,086 |
| James Woodruff Lillie Chief Scientific Officer | Jul 15, 2026 | Sale | −5,393 | $36.99 | $199.49K | 235,098 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 15, 2026 | Sale | −90 | $37.54 | $3.38K | 1,332,316 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 15, 2026 | Sale | −42,738 | $36.99 | $1.58M | 1,332,406 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 15, 2026 | Sale | −18,950 | $36.00 | $682.20K | 1,375,144 |
| Kristopher Hanson General Counsel | Jul 15, 2026 | Sale | −10 | $37.54 | $375 | 155,071 |
| Kristopher Hanson General Counsel | Jul 15, 2026 | Sale | −2,147 | $36.00 | $77.29K | 160,184 |
| Kristopher Hanson General Counsel | Jul 15, 2026 | Sale | −5,103 | $36.99 | $188.76K | 155,081 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MapLight Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,752 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Erin Pennock Foff Officer | Oct 15, 2026 | 15,355 | $119.92K | Oct 15, 2026 | Restricted Stock Unit Grant |
| Christopher A. Kroeger Officer | Oct 15, 2026 | 73,691 | $575.53K | Oct 15, 2026 | Restricted Stock Unit Grant |
| James Woodruff Lillie Officer | Oct 15, 2026 | 11,513 | $89.92K | Oct 15, 2026 | Restricted Stock Unit Grant |
| Robert C. Malenka Director | Oct 15, 2026 | 14,809 | $115.66K | Oct 15, 2026 | Restricted Stock Units |
| Anatol Kreitzer Officer | Oct 15, 2026 | 12,500 | $97.63K | Oct 15, 2026 | Restricted stock unit settlement |
| Kristopher Hanson Officer | Oct 15, 2026 | 9,020 | $70.45K | Oct 15, 2026 | Restricted Stock Unit Grant |
| Jonathan Gillis Officer | Oct 15, 2026 | 10,167 | $79.40K | Oct 15, 2026 | Restricted Stock Unit Grant |
| Kristopher Hanson Officer | Sep 16, 2026 | 16,509 | $199.43K | Sep 16, 2026 | Vested RSU |
| James Woodruff Lillie Officer | Aug 3, 2026 | 22,082 | $287.51K | Aug 3, 2026 | Vested RSU |
| Holdings A/S Novo Former Affiliate | Jul 30, 2026 | 1,600,000 | $24.03M | Jul 30, 2026 | Direct Investment |
| Anatol Kreitzer Officer | Jul 17, 2026 | 17,173 | $639.18K | Jul 17, 2026 | Restricted Stock Units |
| Jonathan Gillis Officer | Jul 17, 2026 | 18,469 | $687.42K | Jul 17, 2026 | Restricted Stock Units |
| Christopher A. Kroeger Officer | Jul 15, 2026 | 152,230 | $5.77M | Jul 15, 2026 | Restricted Stock Unit Grant |
| Robert C. Malenka Director | Jul 15, 2026 | 17,537 | $664.83K | Jul 15, 2026 | Restricted Stock Units |
| Erin Pennock Foff Officer | Jul 15, 2026 | 48,158 | $1.83M | Jul 15, 2026 | Restricted Stock Unit Grant |
See a number that looks wrong?